Chronic Myeloid LeukemiaNCT07413263
Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients
An observational study of Chronic Myeloid Leukemia, run by Assiut University.
Trial summary
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Chronic Myeloid Leukemia
- What is being tested?
- Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
- How many people
- 75 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2026to 30 Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: CML patients
Who may be able to join
- CML patients free medical history
Who cannot join
- diabetic
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
mai mostafa kamal, prof contact
About this study
Official title: Impact of Tyrosine Kinase Inhibitors on Glucose and Lipid Metabolism in Chronic Myeloid Leukemia
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism
Read the detailed description
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism and how danger they drugs be
- Conditions
- Chronic Myeloid Leukemia
- Being tested
- Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
- Medical subject headings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tyrosine kinase Inhibitors (Imatinib & Nilotinib)Drug
these drugs used in CML only
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Assessment of change in HbA1c levels in CML patients treated with TKIs.
Measured: Baseline and 3, 6, 9, and 12 months
Secondary outcomes (1)
Change in lipid profile in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Assessment of changes in lipid profile including total cholesterol, triglycerides, LDL, and HDL in CML patients treated with TKIs.
Measured: Baseline and 3, 6, 9, and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start1 May 2026 (estimated)
- Primary completion30 Dec 2027 (estimated)
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic Myeloid LeukemiaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nancy Atef Abdou Mousa, Assiut University
- Investigators
- Mona mohamed soliman, prof, Principal investigator, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07413263
- Sponsor's protocol ID
- use of TKIs on CML
- Status last verified
- Nov 2025
- First submitted
- 27 Nov 2025
- Last updated
- 18 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hwang SM, Im SH, Rudra D. Signaling networks controlling ID and E protein activity in T cell differentiation and function. Front Immunol. 2022 Aug 2;13:964581. doi: 10.3389/fimmu.2022.964581. eCollection 2022.
PubMed 35983065
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Tyrosine Kinase Inhibitors on Glucose and Lipid Metabolism in Chronic Myeloid Leukemia
- ClinicalTrials.gov ID
- NCT07413263
- Acronym / sponsor ID
- use of TKIs on CML
- Conditions
- Chronic Myeloid Leukemia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 May 2026 (estimated)
- Primary completion
- 30 Dec 2027 (estimated)
- Study completion
- 30 Dec 2028 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism
Detailed description
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism and how danger they drugs be
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- CML patients
Key inclusion criteria (1 listed)
- CML patients free medical history
Key exclusion criteria (1 listed)
- diabetic
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tyrosine kinase Inhibitors (Imatinib & Nilotinib)these drugs used in CML only | Drug | – |
Primary outcome
Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Time frame: Baseline and 3, 6, 9, and 12 months
Assessment of change in HbA1c levels in CML patients treated with TKIs.
1 secondary outcome
Change in lipid profile in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Time frame: Baseline and 3, 6, 9, and 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Background: PubMed 35983065Hwang SM, Im SH, Rudra D. Signaling networks controlling ID and E protein activity in T cell differentiation and function. Front Immunol. 2022 Aug 2;13:964581. doi: 10.3389/fimmu.2022.964581. eCollection 2022.
- Individual participant dataSharing planned: No
Related trials for Chronic Myeloid Leukemia
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
Not yet recruitingPhase 2
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
mai mostafa kamal, prof contact
Mona mohamed soliman, prof principal investigator
Assiut University
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Myeloid Leukemia, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nancy Atef Abdou, doctor (01027607363 ext. 01153253658, nancyatef918@gamil.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (time frame: Baseline and 3, 6, 9, and 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07413263, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.